Therapeutic targeting of the angiopoietin–TIE pathway Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Pipsa Saharinen, Lauri Eklund, Kari Alitalo
The angiopoietin (ANG)–TIE growth factor receptor pathway regulates pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. It has become an attractive pharmacological target for oncological and ophthalmological indications, as well as sepsis, diabetic vasculopathies, organ transplantation and atherosclerosis. Here, Alitalo and colleagues provide an overview of the biology of the ANG–TIE pathway and discuss the development of therapeutics that target it.
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green, Guido Kroemer
Dysregulated autography is associated with a variety of conditions, including cancer, neurodegenerative diseases, cardiovascular disorders and infectious diseases. However, despite significant efforts, no specific modulators of autophagy have yet been moved into the clinic. Here, Galluzzi et al. discuss the therapeutic potential of autophagy modulators and consider the key challenges that have limited their development.
Cancer immunotherapy: T cells get a ride Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 M. Teresa Villanueva
Cancer immunotherapy: T cells get a ride
Neurological disorders: DAMPening damage after stroke Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Megan Cully
Neurological disorders: DAMPening damage after stroke
Neurodegenerative disorders: Ataxin 2 reduction rescues motor defects Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Sarah Crunkhorn
Neurodegenerative disorders: Ataxin 2 reduction rescues motor defects
How much do clinical trials cost? Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Linda Martin, Melissa Hutchens, Conrad Hawkins, Alaina Radnov
This article presents the findings of a recent analysis of the costs of clinical trials, providing benchmark data for companies to assess their performance, as well as indicating cost drivers.
Colorectal cancer drugs market Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-19 Sorcha Cassidy, Basharut A. Syed
The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.
An audience with Jay Bradner Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 Asher Mullard
Nature Reviews Drug Discovery16, 232–233 (2017)Two typographical errors that may have affected the meaning of the answers related to the creation of the Chemical Biology & Therapeutics unit within NIBR and the focus of the NIBR leadership
Regenerative medicine: Targeting adaptor protein interactions for nerve regrowth Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Katie Kingwell
CNS neurons show limited capacity for spontaneous repair after injury, which hampers functional recovery in conditions such as stroke and traumatic brain injury. Now, a study in Neuron has shown that a small molecule, fusicoccin A (FC-A), promotes axon growth after injury in mice
G protein-coupled receptors: Novel probe for MRGPRX2 Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 CrunkhornSarah
The orphan MAS-related G protein-coupled receptor member X2 (MRGPRX2) is expressed primarily in human dorsal root ganglia and mast cells, and has been suggested to modulate pain and itch. Using a high-throughput screen of 5,695 unique compounds, Lansu et al. discovered that many exogenous
Cancer: Identifying synergistic drug combinations Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 CrunkhornSarah
Drug combinations are commonly used to counter drug resistance in cancer therapy. To identify synergistic drug target combinations, Han et al. have developed a scalable CRISPR-based double-knockout system that enables parallel pairwise gene knockout. Application of this system in a chronic myeloid leukaemia (CML)
Viral infections: Targeting host kinases Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 CrunkhornSarah
Targeting host pathways that are exploited by viruses represents a promising antiviral strategy. Bekerman et al. show that the host cell kinases AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK), which activate the host adapter proteins AP1 and AP2, are required by
Antibiotics: Reversing resistance Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 CrunkhornSarah
Acquired Mycobacterium tuberculosis resistance to the commonly used antibiotic ethionamide (ETH) is mediated by mutations in the bacterial enzymatic pathway that is required for biological activation of the drug. Here, Blondiaux et al. identify a series of spiroisoxazoline compounds — named small molecules
Analgesia: Designing out opioid side effects Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 M. Teresa Villanueva
Although opioids are very effective in treating pain that is associated with tissue damage and inflammation, they have important adverse effects, such as drowsiness, constipation, potential respiratory arrest and addiction. By analysing drug–opioid receptor interactions in damaged tissues, as opposed to healthy tissues, Stein and
Trial watch: Trends in clinical trial design complexity Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-18 Kenneth A. Getz, Rafael A. Campo
The challenges of measuring the safety and efficacy of investigational drugs that target chronic, difficult-to-treat or rare diseases in more narrowly defined patient subpopulations have increased the scope of clinical trials and the burden to execute them in the past 15 years. Other factors affecting
The antifungal pipeline: a reality check Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-12 John R. Perfect
Invasive fungal infections are a major medical concern, particularly in immunocompromised patients. In this Review, Perfect discusses the antifungal pipeline, including advances in the currently used drug classes, novel molecular targets, drugs that could be repurposed from other areas and the use of immune-directed therapies.
Market watch: Trends in pharmaceutical company R&D spending: 2005–2015 Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-12 Richa Dixit, Frank S. David
Market watch: Trends in pharmaceutical company R&D spending: 2005–2015
Combination products: modernizing the regulatory paradigm Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-12 Nina L. Hunter, Rachel E. Sherman
New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible and consistent science-based regulatory approach for combination products.
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-05 Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis, Christian D. Klein
Flaviviruses, including dengue and Zika viruses, are of substantial public health concern. Klein and colleagues review the development of broad-spectrum antiviral agents that would target many of the known and potentially unknown flaviviruses. The benefits and caveats of molecules that target either viral proteins or host mechanisms exploited by these viruses are discussed.
Market watch: Landscape for medical countermeasure development Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-05-05 Christopher Milne, Zachary Peter Smith, Ranjana Chakravarthy
Market watch: Landscape for medical countermeasure development
Advances in islet encapsulation technologies Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Tejal Desai, Lonnie D. Shea
Nature Reviews Drug Discovery, doi:10.1038/nrd.2016.232In this article, the University of Edmonton was referred to instead of the University of Alberta and the article cited as reference 10 was incorrect. These errors have been corrected in the online version.
Anticancer therapy: Re-educating macrophages Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 M. Teresa Villanueva
Despite being the main effectors of the innate immune response and programmed to detect and eliminate mutated cells, macrophages can change their phenotype and become pro-tumorigenic in response to cues from the tumour. Given their position within the tumour mass, tumour-associated macrophages (TAMs) are an
Thomas Lynch Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28
Bristol-Myers Squibb has one of the deepest immuno-oncology drug pipelines, with checkpoint inhibitors, T cell and natural killer cell agonists, and metabolic modulators of the tumour microenvironment. Despite a setback with its marketed checkpoint inhibitor nivolumab in a first-line lung cancer setting last year, there are still high hopes for these emerging therapies. In March, the company hired Thomas Lynch — former CEO of Massachusetts General Physicians Organization and Director of the Yale Cancer Center — as its new Chief Scientific Officer, tasked with overseeing the progress of this pipeline. He told Asher Mullard about his R&D priorities, the promise of genomic-based diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.
FDA approves dupilumab for severe eczema Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Asher Mullard
The FDA approved Regeneron and Sanofi's first-in-class candidate dupilumab for the treatment of moderate-to-severe eczema.T helper 2 type responses have emerged as a unifying feature of various inflammatory and allergic diseases, such as eczema and asthma. As a result, type 2 cytokines —
FDA approves first deuterated drug Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Asher Mullard
The FDA approved Teva Pharmaceuticals' deutetrabenazine for chorea associated with Huntington disease, providing the first approval of a drug that contains the heavy hydrogen isotope deuterium.Early adopters first started tinkering with the use of deuterium in drug candidates more than 50 years ago.
FDA approves first drug for primary progressive multiple sclerosis Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Asher Mullard
The FDA approved Roche's ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis (PPMS), wrapping up a 40-year development history for the anti-CD20 monoclonal antibody (mAb). This is the first drug approval for PPMS, a form of the neurodegenerative disease that
CAR T therapies drive into new terrain Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Katie Kingwell
The FDA could soon approve the first chimeric antigen receptor (CAR) T therapies for blood cancers, but this young field is still working on how to address solid tumours, safety concerns and manufacturing issues.
Nine paths to PCSK9 inhibition Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Asher Mullard
A lipid-modulating protein that exemplifies the value of human genetics for target validation has provided a fertile testing ground for new drug modalities including long-acting RNA interference drugs, vaccines against self-antigens, CRISPR therapeutics and small molecules that control ribosomal activity.
Aptamers as targeted therapeutics: current potential and challenges Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Jiehua Zhou, John Rossi
Aptamers as targeted therapeutics: current potential and challenges
Bridging the translational innovation gap through good biomarker practice Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders, Anton Ussi
Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.
Implications of cancer evolution for drug development Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-28 Samra Turajlic, Charles Swanton
Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.
Cancer: Belt and braces for BCR–ABL Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-21 Megan Cully
The breakpoint cluster region–Abelson tyrosine kinase (BCR–ABL) fusion oncoprotein drives chronic myeloid leukaemia (CML). Although therapies targeting BCR–ABL — such as the pioneering compound imatinib — have dramatically improved patient outcomes, many patients need to remain on treatment, and drug resistance can emerge. Writing in
Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-04-21 Sarah Crunkhorn
The development of oral insulin-sensitizing agents to minimize the need for injectable insulin remains a major unmet need in the treatment of diabetes. Now, writing in Nature Chemical Biology, Bottini and colleagues report the identification of the first orally available small-molecule inhibitor of the
Cancer: Bacterium-based immunotherapy Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Sarah Crunkhorn
Anaerobic bacteria can accumulate and proliferate within hypoxic and necrotic regions of solid tumours, stimulating inflammation and triggering an antitumour immune response. Zheng et al. have engineered an attenuated strain of Salmonella typhimurium to overexpress and secrete a heterologous bacterial flagellin (FlaB), which
Cardiovascular disease: Thioredoxin lowers hypertension Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Sarah Crunkhorn
The development of long-lasting antihypertensive therapies represents a crucial unmet need. Hilgers et al. now report that mice overexpressing the redox protein thioredoxin (TRX) are protected from age-related hypertension. Furthermore, injection of aged mice with recombinant human TRX (rhTRX) lowered blood pressure to levels
Drug toxicity: Cardiac safety index for TKIs Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Sarah Crunkhorn
Tyrosine kinase inhibitors (TKIs) represent efficacious anticancer agents, but their use has been linked with severe cardiotoxicity. Here, Sharma et al. generated human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, hiPSC-derived endothelial cells and hiPSC-derived cardiac fibroblasts to evaluate the cardiotoxicities of 21 US FDA-approved
Ocular disorders: Vitamin B3 blocks glaucoma Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Sarah Crunkhorn
The mechanisms that mediate the degeneration of retinal ganglion cells (RGCs) during glaucoma development are unknown. Williams et al. report that decreased levels of NAD+ and mitochondrial dysfunction are among the very first changes to occur in retinas of a mouse model
Viral infections: Reinvigorating exhausted T cells in hepatitis B infection Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Megan Cully
During chronic infection with hepatitis B virus (HBV), T cells become exhausted, and their antiviral response is weakened. An article in Nature Medicine now shows that reducing mitochondrial dysfunction using mitochondrion-targeted antioxidants in CD8+ T cells from patients with chronic HBV infection
Anticancer drugs: All roads lead to EZH2 inhibition Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 M. Teresa Villanueva
Enhancer of zeste homologue 2 (EZH2) — the catalytic subunit of Polycomb repressive complex 2 (PRC2) — mediates transcriptional silencing through trimethylation of histone H3 lysine 27 (H3K27me3). Mutation or overexpression of EZH2 has been linked to numerous types of cancer, and EZH2 inhibitors are
Liver disease: Conscious uncoupling in NASH Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 M. Teresa Villanueva
Non-alcoholic steatohepatitis (NASH) — an inflammatory disease that can progress to cirrhosis and end-stage liver disease — is becoming increasingly common, and there are no approved pharmacological therapies. Wang et al. have now identified that CASP8 and FADD-like apoptosis regulator (CFLAR) can suppress steatohepatitis
Hearing loss: Vector overcomes barrier to gene therapy delivery Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Katie Kingwell
No drug has yet been approved to treat hearing loss, and alternative strategies such as cochlear implants only partly restore hearing function. Now, two papers from researchers at Harvard Medical School report the ability of a synthetic adeno-associated virus (AAV) vector to efficiently deliver a
Infectious diseases: Targeting T cells to treat Chikungunya virus infections Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Sarah Crunkhorn
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes fever and joint pain in humans, potentially leading to chronic debilitating arthritis. There are currently no clinically available therapies that effectively prevent or treat CHIKV infection. Two new studies now demonstrate that the FDA-approved agents abatacept
Jay Bradner Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30
In 2015, the haematologist Jay Bradner made the leap from supervising a few dozen researchers in his lab at the Dana-Farber Cancer Institute to overseeing more than 6,000 scientists at Novartis. As president of the Novartis Institutes for BioMedical Research (NIBR), he has now rolled out his vision for NIBR 2.0 — with an increased focus on chemical biology and open science. He spoke with Asher Mullard about his plans to restructure around emerging drug discovery tools and to forge closer ties with the rest of the scientific community.
TransCelerate makes progress Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Asher Mullard
In 2012, ten biopharmaceutical companies joined forces to launch TransCelerate BioPharma, a non-profit organization aimed at addressing clinical trial inefficiencies (Nat. Rev. Drug Discov.13, 787–788; 2014). Five years on, with 18 companies now signed up, the precompetitive collaborative group has highlighted
FDA approves Novartis's CDK4/6 inhibitor Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Asher Mullard
The FDA approved Novartis's ribociclib for the first-line treatment of hormone receptor (HR)+/HER2− advanced breast cancer in combination with an aromatase inhibitor. This is the second approval for the cyclin-dependent kinase 4 and 6 (CDK4/6) class of kinase inhibitors.CDKs
PARP inhibitors plough on Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Asher Mullard
New clinical data for AstraZeneca's first-in-class poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has raised the bar for a bevy of would-be competitors.The FDA granted accelerated approval to olaparib in 2014 for fourth-line treatment of BRCA-mutated ovarian cancer, but the drug came under pressure last
PRIME time at the EMA Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Asher Mullard
The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
Fragment-based phenotypic screening is a hit Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-30 Monya Baker
Libraries of functionalized small-molecule fragments that can be screened in whole cells could take phenotypic drug discovery to the next level, providing new opportunities against undertargeted proteins.
Bracing for the biosimilar wave Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-31 Asher Mullard
Bracing for the biosimilar wave
Delivery technologies for genome editing Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-24 Hao Yin, Kevin J. Kauffman, Daniel G. Anderson
Genome editing has emerged as an attractive approach to therapeutically manipulate gene expression. Here, Anderson and colleagues provide an overview of genome-editing platforms, focusing on the methods and challenges of intracellular biomacromolecule delivery. Preclinical and clinical trials involving genome-editing technologies are also discussed.
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-24 Seth W. Dickey, Gordon Y. C. Cheung, Michael Otto
Efforts to combat bacterial infections by targeting virulence factors are gaining traction, fuelled by the potential to circumvent the development of antibacterial resistance and recent landmark approvals of antivirulence drugs. Here, Otto and colleagues examine the antivirulence drugs in development, highlighting the most promising targets and strategies, as well as caveats to using this approach.
To cleave or not to cleave: therapeutic gene editing with and without programmable nucleases Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-17 Tod M. Woolf, Channabasavaiah B. Gurumurthy, Frederick Boyce, Eric B. Kmiec
In recent years, pioneering clinical studies involving the use of programmable nucleases to achieve gene editing have begun to evaluate the therapeutic potential of such approaches. For example, Sangamo BioSciences has reported successful proof-of-concept clinical studies to treat HIV infection using an engineered zinc-finger nuclease
Targeting glutamate signalling in depression: progress and prospects Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-17 James W. Murrough, Chadi G. Abdallah, Sanjay J. Mathew
Changes in glutamate signalling have been implicated in major depression, and ketamine, which was recently found to act as a rapid-acting antidepressant, affects glutamate signalling in several ways. Murrough and colleagues give an overview of the development of glutamate-signalling modulators for depression and examine studies on the mechanisms of these agents.
Strategies and challenges for the next generation of antibody–drug conjugates Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-17 Alain Beck, Liliane Goetsch, Charles Dumontet, Nathalie Corvaïa
Antibody–drug conjugate (ADCs), which aim to target highly cytotoxic drugs specifically to cancer cells, are one of the fastest growing classes of anticancer therapeutics, with more than 50 such agents currently in clinical trials. This Review discusses lessons learned and emerging strategies in the development of ADCs, including aspects such as target selection, the development of warheads, the optimization of linkers and new conjugation chemistries, and provides an overview of agents that are currently in clinical trials.
Market watch: Upcoming market catalysts in Q2 2017 Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-17 Eric Ho
Important market catalysts expected in the second quarter of 2017 include regulatory decisions by the FDA on cerliponase alfa (developed by BioMarin) for treatment of CLN2 disease and brigatinib (developed by Takeda) for the treatment of non-small-cell lung cancer (NSCLC), as well as top-line phase
Lessons from immuno-oncology: a new era for cancer nanomedicine? Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-17 Wen Jiang, Hengfeng Yuan, Charles K. Chan, Christina A. von Roemeling, Zuoqin Yan, Irving L. Weissman, Betty Y. S. Kim
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.
Non-kinase targets of protein kinase inhibitors Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-10 Lenka Munoz
Inhibition of proteins other than the intended target by small molecules can lead to the incorrect assignment of biological functions to particular proteins and wasted drug development efforts. Potential inhibition of off-target kinases by kinase inhibitors is often investigated, but kinase inhibitors can also inhibit non-kinases. Munoz examines the growing number of examples of this issue and suggests a systematic strategy to verify which protein is responsible for the effects of a given small molecule.
Marked for death: targeting epigenetic changes in cancer Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-10 Sophia Xiao Pfister, Alan Ashworth
In the past few years, it has become clear that mutations in epigenetic regulatory genes are common in human cancers. Therapeutic strategies are now being developed to target cancers with mutations in these genes using specific chemical inhibitors. In addition, a complementary approach based on
Patent watch: Patent insight into polymer-free drug-eluting stents Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-10 Vadim Demidov, Daniel Currie, Justin Wen
Improved precision is a key innovation in controlled-release drug delivery systems, including drug-eluting stents (DESs), which are used in the treatment of life-threatening vascular diseases. These inventive devices replaced the bare metal stents previously used in angioplasty to reduce post-surgery inflammation and restenosis via slow-releasing
Trends in the market for antihypertensive drugs Nat. Rev. Drug. Disc. (IF 47.120) Pub Date : 2017-03-10 M. Adam Ali, Salman Rizvi, Basharut A. Syed
This analysis provides an overview of novel antihypertensive products, many of which are fixed-dose combinations of different drug classes, and provides an outlook on their likely impact on the market.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
- Acc. Chem. Res.
- ACS Appl. Mater. Interfaces
- ACS Catal.
- ACS Cent. Sci.
- ACS Chem. Biol.
- ACS Energy Lett.
- ACS Macro Lett.
- ACS Nano
- ACS Omega
- ACS Sens.
- ACS Sustainable Chem. Eng.
- Adv. Electron. Mater.
- Adv. Energy Mater.
- Adv. Funct. Mater.
- Adv. Healthcare Mater.
- Adv. Mater.
- Adv. Synth. Catal.
- AlChE J.
- Anal. Chem.
- Anal. Chim. Acta
- Angew. Chem. Int. Ed.
- Annu. Rev. Microbiol.
- Appl. Catal. A Gen.
- Appl. Catal. B Environ.
- Appl. Energy
- J. Am. Chem. Soc.
- J. Catal.
- J. Chem. Phys.
- J. Chem. Theory Comput.
- J. Chromatogr. A
- J. Chromatogr. B
- J. Control. Release
- J. Electrochem. Soc.
- J. Mater. Chem. A
- J. Mater. Chem. B
- J. Mater. Chem. C
- J. Med. Chem.
- J. Nat. Prod.
- J. Org. Chem.
- J. Phys. Chem. A
- J. Phys. Chem. B
- J. Phys. Chem. C
- J. Phys. Chem. Lett.
- J. Power Sources
- Nano Energy
- Nano Lett.
- Nano Res.
- Nano Today
- Nat. Biomed. Eng.
- Nat. Biotechnol.
- Nat. Cell. Biol.
- Nat. Chem. Biol.
- Nat. Commun.
- Nat. Genet.
- Nat. Immunol.
- Nat. Med.
- Nat. Methods
- Nat. Microbiol.
- Nat. Neurosci.
- Nat. Photon.
- Nat. Phys.
- Nat. Prod. Rep.
- Nat. Rev. Chem.
- Nat. Rev. Drug. Disc.
- Nat. Rev. Mater.
- Nat. Rev. Microbiol.
- Nature Chem.
- Nature Energy
- Nature Geosci.
- Nature Mater.
- Nature Nanotech.
- NPG Asia Mater.